See ANZUPGO Results

Think you might have CHE? TAKE THE ASSESSMENT

AT 4 MONTHS:

UP TO

4X MORE
PEOPLE

SAW CLEAR OR ALMOST-CLEAR
SKIN

ANZUPGO vs
non-medicated cream

Study 1: 20% vs 10%
Study 2: 29% vs 7%

In Study 1: 325 people used ANZUPGO, and 162 people used the non-medicated cream. In Study 2: 313 people used ANZUPGO, and 159 people used the non-medicated cream.

See Before & After photos

MORE THAN

2X AS MANY
PEOPLE

HAD SIGNIFICANT ITCH RELIEF

ANZUPGO vs
non-medicated cream

Study 1: 47% vs 23%
Study 2: 47% vs 20%

In Study 1: 323 people used ANZUPGO, and 161 people used the non-medicated cream. In Study 2: 309 people used ANZUPGO, and 156 people used the non-medicated cream.

Hear from study participants

UP TO

2X MORE
PEOPLE

HAD SIGNIFICANT PAIN RELIEF

ANZUPGO vs
non-medicated cream

Study 1: 49% vs 28%
Study 2: 49% vs 23%

In Study 1: 291 people used ANZUPGO, and 149 people used the non-medicated cream. In Study 2: 294 people used ANZUPGO, and 141 people used the non-medicated cream.

Hear from study participants

SIGNIFICANTLY CLEARER
SKIN AS EARLY AS 4 WEEKS

ANZUPGO vs non-medicated cream

Study 1: 15% vs 5%
Study 2: 15% vs 8%

In Study 1: 325 people used ANZUPGO, and 162 people used the non-medicated cream.
In Study 2: 313 people used ANZUPGO, and 159 people used the non-medicated cream.

Actor portrayal.

BEFORE & AFTER:
SEE THE DIFFERENCE

Explore photos from the ANZUPGO clinical studies here.

Throughout the studies, participants were given a score from 0 to 4.

0 = clear skin
4 = severe CHE

Success was defined as achieving both:

An end score of 0 (clear) or 1 (almost-clear)
At least a 2-point drop in score from the beginning of the study

ANZUPGO helped many study participants get clearer skin. Individual results may vary.

CHE relief IN THEIR OWN WORDS

ANZUPGO helped many adults with moderate-to-severe CHE get relief from itch and pain.

I'm not in as much pain, and I'm not as uncomfortable scratching and waking myself up or sitting at work scratching.

Participant in ANZUPGO clinical study
Individual results may vary.

I can't even remember the last time I had pain during the night.

Participant in ANZUPGO clinical study
Individual results may vary.

Itching is mild and only from time to time. It's completely different. Like a 180 turnaround.

Participant in ANZUPGO clinical study
Individual results may vary.

I hardly have any pain...it's like the pain is almost gone most of the time.

Participant in ANZUPGO clinical study
Individual results may vary.

ANZUPGO demonstrated safety profile

ANZUPGO demonstrated safety profile

In studies, the most common side effects reported in less than 1% of ANZUPGO treated patients include:

application site reactions, including pain, tingling, itching and redness
bacterial skin infections, including finger cellulitis, and nail infections
low white blood cells

These are not all of the possible side effects of ANZUPGO.

The safety of ANZUPGO has been evaluated in a long-term clinical study for
UP TO
1 YEAR

Actor portrayal.

Sign Up
and Go

Receive emails about ANZUPGO and tips for your CHE
treatment journey.

INDICATION

What is ANZUPGO?

ANZUPGO is a prescription medicine used on the skin (topical) to treat moderate to severe chronic hand eczema (CHE) in adults who are not well-controlled with or cannot use topical corticosteroids.

The use of ANZUPGO along with other JAK inhibitors or strong immunosuppressants is not recommended.

Please see full Prescribing Information and Medication Guide.

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

ANZUPGO is for use on the skin (topical use) only. Do not use ANZUPGO in or on your eyes, mouth, or vagina.

What is the most important information I should know about ANZUPGO?

ANZUPGO may cause serious side effects, including:

Serious Infections: ANZUPGO may increase your risk of infections. ANZUPGO contains delgocitinib. Delgocitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth or applying on the skin, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections.

ANZUPGO should not be used in people with an active, serious infection. You should not start using ANZUPGO if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) or eczema herpeticum (a blistery, painful skin rash) during treatment with ANZUPGO.

Before starting ANZUPGO, tell your healthcare provider if you:

are being treated for an infection or have an infection that does not go away or that keeps coming back
have TB or have been in close contact with someone with TB
have had shingles (herpes zoster)
have had hepatitis B or C
think you have an infection or have symptoms of an infection such as fever, sweating, or chills; muscle aches; cough or shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinating more often than usual; and/or feeling very tired

After starting ANZUPGO, call your healthcare provider right away if you have any symptoms of an infection. ANZUPGO can make you more likely to get infections or make worse any infections that you have. If you get a serious infection, your healthcare provider may stop your treatment with ANZUPGO until your infection is controlled.

Non-melanoma skin cancer. ANZUPGO may increase your risk of certain non-melanoma skin cancers. Your healthcare provider will regularly check your skin during your treatment with ANZUPGO.

Avoid sunlamps and limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun, and use a broad-spectrum sunscreen
Tell your healthcare provider if you have ever had any type of cancer

Potential risks from Janus kinase (JAK) inhibition. It is not known whether using ANZUPGO has the same risks as taking oral or other topical JAK inhibitors. Increased risk of death (all causes) has happened in people who were 50 years of age and older with at least one heart disease (cardiovascular) risk factor who were taking a JAK inhibitor used to treat rheumatoid arthritis (RA) compared to people taking another medicine in a class of medicines called TNF blockers. ANZUPGO is not for use in people with RA. Oral or other topical JAK inhibitors have also caused increased cholesterol.

Before using ANZUPGO, tell your healthcare provider about all your medical conditions, including if you:

have an infection
have recently received or are scheduled to receive a vaccine. People who use ANZUPGO should not receive live vaccines right before starting, during treatment, or right after treatment with ANZUPGO
are pregnant or plan to become pregnant. It is not known if ANZUPGO will harm your unborn baby
are breastfeeding or plan to breastfeed. It is not known if ANZUPGO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with ANZUPGO. If you use ANZUPGO while breastfeeding, avoid touching the nipple and surrounding area right away after applying ANZUPGO to your hands and wrists

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the most common side effects of ANZUPGO?

application site reactions, including pain, tingling, itching, and redness; bacterial skin infections, including finger cellulitis and nail infections; and low white blood cells

These are not all of the possible side effects of ANZUPGO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information and Medication Guide.

Read more Collapse

*See full Terms, Conditions, and Eligibility Rules.